Rekomendacje Polskiego Towarzystwa Ginekologii Onkologicznej dotyczące diagnostyki i leczenia raka piersi u kobiet ciężarnych

• Authors: Paweł Basta

Title variants

EN

Recommendations of the Polish Gynecological Oncology Society on the diagnosis and treatment of breast cancer during pregnancy

• Languages of publication: EN

Discipline

• MEDICINE: MEDICINE

• Publisher: Medical Communications
• Journal: Current Gynecologic Oncology
• Year: 2014
• Volume: 12
• Issue: 1
• Pages: 31-42

Contributors

author

Paweł Basta

• I Katedra Chirurgii Uniwersytetu Jagiellońskiego, Collegium Medicum. Kierownik: prof. dr hab. n. med. Jan Kulig Oddział Kliniczny Ginekologii i Onkologii, Szpital Uniwersytecki w Krakowie. Kierownik: prof. dr hab. n. med. Antoni Basta. Dr n. med. Paweł Basta, Oddział Kliniczny Ginekologii i Onkologii, Szpital Uniwersytecki w Krakowie, ul. Kopernika 23, 31-501 Kraków, tel.: [phone]

References

• 1. Pentheroudakis G., Orecchia R., Hoekstra H.J. i wsp.: Cancer, fertility and pregnancy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2010; 21: 266–273.
• 2. Murphy C., Mallam D., Stein S. i wsp.: Current or recent pregnancy is associated with adverse pathologic features but not impaired survival in early breast cancer. Cancer 2012; 118: 3254–3259.
• 3. Stensheim H., Møller B., van Dijk T. i wsp.: Cause-specific survival for women diagnosed with cancer during pregnancy or lactation: a registry-based cohort study. J. Clin. Oncol. 2009; 27: 45–51.
• 4. Beadle B.M., Woodward W.A., Middleton L.P. i wsp.: The impact of pregnancy on breast cancer outcomes in women ≤35 years. Cancer 2009; 115: 1174–1184.
• 5. Amant F., von Minckwitz G., Han S.N. i wsp.: Prognosis of women with primary breast cancer diagnosed during pregnancy: results from an international collaborative study. J. Clin. Oncol. 2013; 31: 2532–2539.
• 6. Mathelin C., Annane K., Treisser A. i wsp.: Pregnancy and post-partum breast cancer: a prospective study. Anticancer Res. 2008; 28: 2447–2452.
• 7. Johansson A.L., Andersson T.M., Hsieh C.C. i wsp.: Increased mortality in women with breast cancer detected during pregnancy and different periods postpartum. Cancer Epidemiol. Biomarkers Prev. 2011; 20: 1865–1872.
• 8. Azim H.A. Jr, Santoro L., Russell-Edu W. i wsp.: Prognosis of pregnancy-associated breast cancer: a meta-analysis of 30 studies. Cancer Treat. Rev. 2012; 38: 834–842.
• 9. Loibl S., von Minckwitz G., Gwyn K. i wsp.: Breast carcinoma during pregnancy. International recommendations from an expert meeting. Cancer 2006; 106: 237–246.
• 10. Nicklas A.H., Baker M.E.: Imaging strategies in the pregnant cancer patient. Semin. Oncol. 2000; 27: 623–632.
• 11. Mazonakis M., Varveris H., Damilakis J. i wsp.: Radiation dose to conceptus resulting from tangential breast irradiation. Int. J. Radiat. Oncol. Biol. Phys. 2003; 55: 386–391.
• 12. Yang W.T., Dryden M.J., Gwyn K. i wsp.: Imaging of breast cancer diagnosed and treated with chemotherapy during pregnancy. Radiology 2006; 239: 52–60.
• 13. Novak Z., Thurmond A.S., Ross P.L. i wsp.: Gadolinium- DTPA transplacental transfer and distribution in fetal tissue in rabbits. Invest. Radiol. 1993; 28: 828–830.
• 14. Birchard K.R., Brown M.A., Hyslop W.B. i wsp.: MRI of acute abdominal and pelvic pain in pregnant patients. Am. J. Roentgenol. 2005; 184: 452–458.
• 15. Webb J.A., Thomsen H.S., Morcos S.K.; Members of Contrast Media Safety Committee of European Society of Urogenital Radiology (ESUR): The use of iodinated and gadolinium contrast media during pregnancy and lactation. Eur. Radiol. 2005; 15: 1234–1240.
• 16. Schackmuth E.M., Harlow C.L., Norton L.W.: Milk fistula: a complication after core breast biopsy. Am. J. Roentgenol. 1993; 161: 961–962.
• 17. Dominici L.S., Kuerer H.M., Babiera G. i wsp.: Wound complications from surgery in pregnancy-associated breast cancer (PABC). Breast Dis. 2010; 31: 1–5.
• 18. Goldhirsch A., Winer E.P., Coates A.S. i wsp.; Panel members: Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann. Oncol. 2013; 24: 2206–2223.
• 19. National Comprehensive Cancer Network: Clinical Practice Guidelines in Oncology. Breast Cancer: Version 1.2014. Adres: www.nccn.com.
• 20. Amant F., Loibl S., Neven P., Van Calsteren K.: Breast cancer in pregnancy. Lancet 2012; 379: 570–579.
• 21. Rovera F., Frattini F., Coglitore A. i wsp.: Breast cancer in pregnancy. Breast J. 2010; 16: S22–S25.
• 22. Navrozoglou I., Vrekoussis T., Kontostolis E. i wsp.: Breast cancer during pregnancy: a mini-review. Eur. J. Surg. Oncol. 2008; 34: 837–843.
• 23. Vinatier E., Merlot B., Poncelet E. i wsp.: Breast cancer during pregnancy. Eur. J. Obstet. Gynecol. Reprod. Biol. 2009; 147: 9–14.
• 24. Amant F., Deckers S., Van Calsteren K. i wsp.: Breast cancer in pregnancy: recommendations of an international consensus meeting. Eur. J. Cancer 2010; 46: 3158–3168.
• 25. Keleher A., Wendt R. 3rd, Delpassand E. i wsp.: The safety of lymphatic mapping in pregnant breast cancer patients using Tc-99m sulfur colloid. Breast J. 2004; 10: 492–495.
• 26. Montgomery L.L., Thorne A.C., Van Zee K.J. i wsp.: Isosulfan blue dye reactions during sentinel lymph node mapping for breast cancer. Anesth. Analg. 2002; 95: 385–388.
• 27. Raut C.P., Hunt K.K., Akins J.S. i wsp.: Incidence of anaphylactoid reactions to isosulfan blue dye during breast carcinoma lymphatic mapping in patients treated with preoperative prophylaxis: results of a surgical prospective clinical practice protocol. Cancer 2005; 104: 692–699.
• 28. Cardonick E., Dougherty R., Grana G. i wsp.: Breast cancer during pregnancy: maternal and fetal outcomes. Cancer J. 2010; 16: 76–82.
• 29. Martin D.D.: Review of radiation therapy in the pregnant cancer patient. Clin. Obstet. Gynecol. 2011; 54: 591–601.
• 30. Streffer C., Shore R., Konermann G. i wsp.: Biological effects after prenatal irradiation (embryo, foetus). A report of the International Commission on Radiological Protection. Ann. ICRP 2003; 33: 205–206.
• 31. Galimberti V., Ciocca M., Leonardi M.C. i wsp.: Is electron beam intraoperative radiotherapy (ELIOT) safe in pregnant women with early breast cancer? In vivo dosimetry to assess fetal dose. Ann. Surg. Oncol. 2009; 16: 100–105.
• 32. Ring A.E., Smith I.E., Jones A. i wsp.: Chemotherapy for breast cancer during pregnancy: an 18-year experience from five London teaching hospitals. J. Clin. Oncol. 2005; 23: 4192–4197.
• 33. Hahn K.M., Johnson P.H., Gordon N. i wsp.: Treatment of pregnant breast cancer patients and outcomes of children exposed to chemotherapy in utero. Cancer 2006; 107: 1219–1226.
• 34. Elledge R.M., Ciocca D.R., Langone G., McGuire W.L.: Estrogen receptor, progesterone receptor, and HER-2/neu protein in breast cancers from pregnant patients. Cancer 1993; 71: 2499–2506.
• 35. Azim H.A. Jr, Del Mastro L., Scarfone G., Peccatori F.A.: Treatment of breast cancer during pregnancy: regimen selection, pregnancy monitoring and more… Breast 2011; 20: 1–6.
• 36. Azim H.A. Jr, Peccatori F.A., Pavlidis N.: Treatment of the pregnant mother with cancer: a systematic review on the use of cytotoxic, endocrine, targeted agents and immunotherapy during pregnancy. Part I: Solid tumors. Cancer Treat. Rev. 2010; 36: 101–109.
• 37. Mir O., Berveiller P., Rouzier R. i wsp.: Chemotherapy for breast cancer during pregnancy: is epirubicin safe? Ann. Oncol. 2008; 19: 1814–1815.
• 38. Van Calsteren K., Heyns L., DeSmet F. i wsp.: Cancer during pregnancy: an analysis of 215 patients emphasizing the obstetrical and the neonatal outcomes. J. Clin. Oncol. 2010; 28: 683–689.
• 39. Zagouri F., Sergentanis T.N., Chrysikos D. i wsp.: Taxanes for breast cancer during pregnancy: a systematic review. Clin. Breast Cancer 2013; 13: 16–23.
• 40. Mir O., Berveiller P., Goffinet F. i wsp.: Taxanes for breast cancer during pregnancy: a systematic review. Ann. Oncol. 2010; 21: 425–426.
• 41. Zagouri F., Psaltopoulou T., Dimitrakakis C. i wsp.: Challenges in managing breast cancer during pregnancy. J. Thorac. Dis. 2013; 5 supl. 1: S62–S67.
• 42. Berveiller P., Mir O.: Taxanes during pregnancy: probably safe, but still to be optimized. Oncology 2012; 83: 239–240.
• 43. Azim H.A. Jr, Azim H., Peccatori F.A.: Treatment of cancer during pregnancy with monoclonal antibodies: a real challenge. Expert Rev. Clin. Immunol. 2010; 6: 821–826.
• 44. Zagouri F., Sergentanis T.N., Chrysikos D. i wsp.: Trastuzumab administration during pregnancy: a systematic review and meta-analysis. Breast Cancer Res. Treat. 2013; 137: 349–357.
• 45. Goodyer M.J., Ismail J.R., O’Reilly S.P. i wsp.: Safety of trastuzumab (Herceptin) during pregnancy: two case reports. Cases J. 2009; 2: 9329.
• 46. Waterston A.M., Graham J.: Effect of adjuvant trastuzumab on pregnancy. J. Clin. Oncol. 2006; 24: 321–322.
• 47. Azim H.A. Jr, Peccatori F.A., Liptrott S.J. i wsp.: Breast cancer and pregnancy: how safe is trastuzumab? Nat. Rev. Clin. Oncol. 2009; 6: 367–370.
• 48. Pentsuk N., van der Laan J.W.: An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies. Birth Defects Res. B. Dev. Reprod. Toxicol. 2009; 86: 328–344.
• 49. Abusief M.E., Missmer S.A., Ginsburg E.S. i wsp.: The effects of paclitaxel, dose density, and trastuzumab on treatment- related amenorrhea in premenopausal women with breast cancer. Cancer 2010; 116: 791–798.
• 50. Azim H.A. Jr, Metzger-Filho O., de Azambuja E. i wsp.: Pregnancy occurring during or following adjuvant trastuzumab in patients enrolled in the HERA trial (BIG 01-01). Breast Cancer Res. Treat. 2012; 133: 387–391.
• 51. Kelly H., Graham M., Humes E. i wsp.: Delivery of a healthy baby after first-trimester maternal exposure to lapatinib. Clin. Breast Cancer 2006; 7: 339–341.
• 52. Tewari K., Bonebrake R.G., Asrat T., Shanberg A.M.: Ambiguous genitalia in infant exposed to tamoxifen in utero. Lancet 1997; 350: 183.
• 53. Isaacs R.J., Hunter W., Clark K.: Tamoxifen as systemic treatment of advanced breast cancer during pregnancy – case report and literature review. Gynecol. Oncol. 2001; 80: 405–408.
• 54. Viswanathan S., Ramaswamy B.: Pregnancy-associated breast cancer. Clin. Obstet. Gynecol. 2011; 54: 546–555.
• 55. Hahn K.M., Johnson P.H., Gordon N. i wsp.: Treatment of pregnant breast cancer patients and outcomes of children exposed to chemotherapy in utero. Cancer 2006; 107: 1219–1226.
• 56. Bilgin K., Yaramiş A., Haspolat K. i wsp.: A randomized trial of granulocyte- macrophage colony-stimulating factor in neonates with sepsis and neutropenia. Pediatrics 2001; 107: 36–41.
• 57. Schibler K.R., Osborne K.A., Leung L.Y. i wsp.: A randomized, placebo-controlled trial of granulocyte colony-stimulating factor administration to newborn infants with neutropenia and clinical signs of early-onset sepsis. Pediatrics 1998; 102: 6–13.
• 58. Sorosky J.I., Sood A.K., Buekers T.E.: The use of chemotherapeutic agents during pregnancy. Obstet. Gynecol. Clin. North Am. 1997; 24: 591–599.
• 59. Amant F., Van Calsteren K., Halaska M.J. i wsp.: Long-term cognitive and cardiac outcomes after prenatal exposure to chemotherapy in children aged 18 months or older: an observational study. Lancet Oncol. 2012; 13: 256–264.
• 60. Tamaru S., Kikuchi A., Takagi K. i wsp.: Neurodevelopmental outcomes of very low birth weight and extremely low birth weight infants at 18 months of corrected age associated with prenatal risk factors. Early Hum. Dev. 2011; 87: 55–59.
• 61. Dunn J.S. Jr, Anderson C.D., Brost B.C.: Breast carcinoma metastatic to the placenta. Obstet. Gynecol. 1999; 94: 846.
• 62. Yu J.H., Kim M.J., Cho H. i wsp.: Breast diseases during pregnancy and lactation. Obstet. Gynecol. Sci. 2013; 56: 143–159.
• 63. Durodola J.I.: Administration of cyclophosphamide during late pregnancy and early lactation: a case report. J. Natl Med. Assoc. 1979; 71: 165–166.
• 64. Cardonick E., Usmani A., Ghaffar S.: Perinatal outcomes of a pregnancy complicated by cancer, including neonatal follow-up after in utero exposure to chemotherapy: results of an international registry. Am. J. Clin. Oncol. 2010; 33: 221–228.
• 65. Daneman R., Zhou L., Kebede A.A., Barres BA.: Pericytes are required for blood-brain barrier integrity during embryogenesis. Nature 2010; 468: 562–566.
• 66. Virgintino D., Errede M., Girolamo F. i wsp.: Fetal bloodbrain barrier P-glycoprotein contributes to brain protection during human development. J. Neuropathol. Exp. Neurol. 2008; 67: 50–61.
• 67. Saunders N.R., Knott G.W., Dziegielewska K.M.: Barriers in the immature brain. Cell. Mol. Neurobiol. 2000; 20: 29–40.

• Document Type: communication